[go: up one dir, main page]

NO20025002L - Anvendelse av mometasonfuroat ved behandling av luftveis- og lungesykdommer - Google Patents

Anvendelse av mometasonfuroat ved behandling av luftveis- og lungesykdommer

Info

Publication number
NO20025002L
NO20025002L NO20025002A NO20025002A NO20025002L NO 20025002 L NO20025002 L NO 20025002L NO 20025002 A NO20025002 A NO 20025002A NO 20025002 A NO20025002 A NO 20025002A NO 20025002 L NO20025002 L NO 20025002L
Authority
NO
Norway
Prior art keywords
treatment
mometasone furoate
respiratory
pulmonary diseases
allergic
Prior art date
Application number
NO20025002A
Other languages
English (en)
Other versions
NO328698B1 (no
NO20025002D0 (no
Inventor
Joel A Sequeira
Francis M Cuss
Keith B Nolop
Imtiaz A Chaudry
Nagamani Nagabhushan
James E Patrick
Mitchell Cayen
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20025002(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20025002L publication Critical patent/NO20025002L/no
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20025002D0 publication Critical patent/NO20025002D0/no
Publication of NO328698B1 publication Critical patent/NO328698B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20025002A 1994-01-27 2002-10-17 Anvendelse av mometasonfuroat for fremstilling av et torrpulverinhaleringsmedikament for behandling av sykdommer i de ovre eller nedre luftveier eller lunger NO328698B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18837294A 1994-01-27 1994-01-27
PCT/US1995/000550 WO1995020393A1 (en) 1994-01-27 1995-01-26 Use of mometasone furoate for treating airway passage and lung diseases

Publications (3)

Publication Number Publication Date
NO20025002L true NO20025002L (no) 1996-09-26
NO20025002D0 NO20025002D0 (no) 2002-10-17
NO328698B1 NO328698B1 (no) 2010-04-26

Family

ID=22692858

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19963132A NO314535B1 (no) 1994-01-27 1996-07-26 Anvendelse av en vandig suspensjon av mometasonfuroat for fremstilling av et medikament for behandling av allergisk eller arstidsbestemt rhinitt, samt behandling av astma og inflammatoriske sykdommer i de ovre og nedre luftveier
NO20025002A NO328698B1 (no) 1994-01-27 2002-10-17 Anvendelse av mometasonfuroat for fremstilling av et torrpulverinhaleringsmedikament for behandling av sykdommer i de ovre eller nedre luftveier eller lunger

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19963132A NO314535B1 (no) 1994-01-27 1996-07-26 Anvendelse av en vandig suspensjon av mometasonfuroat for fremstilling av et medikament for behandling av allergisk eller arstidsbestemt rhinitt, samt behandling av astma og inflammatoriske sykdommer i de ovre og nedre luftveier

Country Status (29)

Country Link
EP (6) EP0740550B1 (no)
JP (6) JP3480736B2 (no)
KR (1) KR100234864B1 (no)
CN (4) CN100441192C (no)
AT (5) ATE518520T1 (no)
AU (1) AU691880B2 (no)
CA (1) CA2182086C (no)
CO (1) CO4340692A1 (no)
CY (2) CY2616B2 (no)
CZ (1) CZ219196A3 (no)
DE (1) DE69526425T2 (no)
DK (3) DK2156840T3 (no)
ES (3) ES2369516T3 (no)
FI (2) FI122395B (no)
HK (4) HK1040911B (no)
HU (1) HU227837B1 (no)
IL (1) IL112459A (no)
MX (1) MX9602246A (no)
MY (1) MY114665A (no)
NO (2) NO314535B1 (no)
NZ (1) NZ279979A (no)
PE (1) PE44995A1 (no)
PL (1) PL315575A1 (no)
PT (3) PT1174138E (no)
SG (1) SG47387A1 (no)
SK (1) SK283338B6 (no)
TW (1) TW329387B (no)
WO (1) WO1995020393A1 (no)
ZA (1) ZA95637B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
JP4228116B2 (ja) * 1996-05-09 2009-02-25 ゼニス・オペレイションズ・プロプライエタリー・リミテッド 喘息および気道の疾患の治療
ES2159148T3 (es) * 1996-08-29 2001-09-16 Schering Corp Formulaciones en aerosol de furoato de mometasona libres de clorofluorocarbonos.
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US6495167B2 (en) 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
US6503537B2 (en) 1997-03-20 2003-01-07 Schering Corporation Preparation of powder agglomerates
PL192441B1 (pl) * 1997-03-20 2006-10-31 Schering Corp Sposób wytwarzania aglomeratów i postać dawkowania środka farmakologicznie aktywnego
CA2305256C (en) * 1997-10-09 2005-05-17 Schering Corporation Mometasone furoate suspensions for nebulization
MY133181A (en) * 1998-09-10 2007-10-31 Schering Corp Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
ES2284531T3 (es) * 1999-10-08 2007-11-16 Schering Corporation Tratamiento nasal topico usando desloratadina y furoato de mometasona.
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
AU2001278115A1 (en) * 2000-08-04 2002-02-18 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
PT1344526E (pt) * 2000-12-22 2008-06-18 Nippon Shinyaku Co Ltd Profiláticos/remédios para doenças inflamatórias das vias aéreas
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
EP1667687A1 (en) * 2003-09-26 2006-06-14 Schering Corporation Pulmonary disease treatment
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
JP2007509941A (ja) * 2003-10-28 2007-04-19 グラクソ グループ リミテッド ラクトース無水物を用いる吸入医薬製剤およびその投与方法
RS51335B (sr) * 2004-01-21 2011-02-28 Schering Corporation Metoda lečenja akutnog rinosinusitisa
WO2006043655A1 (ja) * 2004-10-22 2006-04-27 Ono Pharmaceutical Co., Ltd. 吸入用医薬組成物
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2705681C (en) 2007-11-13 2013-06-18 Meritage Pharma, Inc. Corticosteroid compositions
US20090123390A1 (en) 2007-11-13 2009-05-14 Meritage Pharma, Inc. Compositions for the treatment of gastrointestinal inflammation
WO2010013240A1 (en) 2008-07-31 2010-02-04 Dekel Pharmaceuticals Ltd. Compositions and methods for treating inflammatory disorders
WO2010021636A1 (en) * 2008-08-20 2010-02-25 The Regents Of The University Of California Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
US20120022032A1 (en) * 2008-10-10 2012-01-26 Schering Corporation Corticosteroid compositions and methods of treatments thereof
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
HK1215674A1 (zh) 2013-10-04 2016-09-09 Glenmark Pharmaceuticals Limited 结合使用莫米松和奥洛他定治疗过敏性鼻炎
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107260665B (zh) * 2016-04-08 2021-03-30 天津金耀集团有限公司 一种吸入用糠酸莫米松混悬液组合物
HUE071622T2 (hu) 2018-02-23 2025-09-28 Glenmark Specialty Sa Allergiás Rhinitis kezelése gyermekgyógyászati alanyoknál mometazon és olopatadin kombinációjával
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN113933415B (zh) * 2021-09-30 2023-03-24 北京阳光德美医药科技有限公司 一种hplc-ms/ms测定人血浆中糠酸酯浓度的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY1359A (en) 1981-02-02 1987-08-07 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
US4731447A (en) 1985-05-13 1988-03-15 Schering Corporation Process for preparing piperidylidene dihydro-dibenzo(a,d)-cycloheptenes or aza-derivatives thereof
US4972830A (en) 1985-07-31 1990-11-27 Vortran Medical Technology, Inc. Inhalation device and method
US4873335A (en) 1986-03-12 1989-10-10 Schering Corporation 3-phenethyl-2-benzene-amides or aza-derivatives thereof
US4910192A (en) * 1987-12-04 1990-03-20 Sri International Topically active steroidal anti-inflammatory agents
DE69027319T2 (de) * 1989-04-28 1996-11-21 Riker Laboratories Inc., Northridge, Calif. Inhalationsvorrichtung für trockenpulver
WO1991014422A1 (en) * 1990-03-23 1991-10-03 Minnesota Mining And Manufacturing Company The use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
IL99437A (en) 1990-09-10 1995-05-29 Schering Corp Mometasone furoate monohydrate process for making same and pharmaceutical compositions
AU679165B2 (en) * 1990-10-16 1997-06-26 John Lezdey Treatment of inflammation
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
DE69233659T2 (de) * 1991-06-10 2007-09-13 Schering Corp. Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
ATE134509T1 (de) * 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
DK0592601T3 (da) 1991-06-26 1996-06-10 Schering Corp Inhalationsindretning til medikamenter i pulverform
DE4140689B4 (de) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU663905B2 (en) * 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
DK0616525T3 (da) * 1991-12-12 1996-01-08 Glaxo Group Ltd Medikamenter
ATE145819T1 (de) * 1992-03-10 1996-12-15 Fisons Plc Inhalierbare arzneimittel
GB9207400D0 (en) * 1992-04-02 1992-05-13 Smithkline Beecham Plc Novel use
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias

Also Published As

Publication number Publication date
EP0740550B1 (en) 2002-04-17
EP1174138B1 (en) 2011-08-03
JP2008285497A (ja) 2008-11-27
CN100441192C (zh) 2008-12-10
IL112459A (en) 1999-04-11
EP1174139A3 (en) 2002-01-30
SK283338B6 (sk) 2003-06-03
DK0740550T3 (da) 2002-06-24
ATE519489T1 (de) 2011-08-15
PT2156840E (pt) 2011-10-18
CN1531967A (zh) 2004-09-29
HK1040918A1 (en) 2002-06-28
NO328698B1 (no) 2010-04-26
PE44995A1 (es) 1995-12-18
AU691880B2 (en) 1998-05-28
CZ219196A3 (en) 1996-12-11
EP1174138A3 (en) 2002-01-30
HK1040911A1 (en) 2002-06-28
FI20115742L (fi) 2011-07-08
WO1995020393A1 (en) 1995-08-03
NZ279979A (en) 2001-03-30
HUT74884A (en) 1997-02-28
HU227837B1 (en) 2012-05-02
HK1135331A1 (en) 2010-06-04
JP2012036222A (ja) 2012-02-23
JP2003313128A (ja) 2003-11-06
IL112459A0 (en) 1995-03-30
MX9602246A (es) 1997-07-31
FI962828L (fi) 1996-07-12
CN1139384A (zh) 1997-01-01
CA2182086A1 (en) 1995-08-03
EP1174138A2 (en) 2002-01-23
ZA95637B (en) 1995-07-26
PT740550E (pt) 2002-08-30
EP2156840A3 (en) 2010-05-19
CN100358528C (zh) 2008-01-02
CN101156860A (zh) 2008-04-09
JP5247265B2 (ja) 2013-07-24
DK1174138T3 (da) 2011-11-21
DK2156840T3 (da) 2011-11-21
NO20025002D0 (no) 2002-10-17
HK1040912A1 (en) 2002-06-28
EP1174139B1 (en) 2011-09-21
JP3480736B2 (ja) 2003-12-22
CO4340692A1 (es) 1996-07-30
KR100234864B1 (ko) 1999-12-15
SK82296A3 (en) 1997-03-05
EP2156840B1 (en) 2011-08-10
FI962828A0 (fi) 1996-07-12
NO314535B1 (no) 2003-04-07
ES2369516T3 (es) 2011-12-01
HK1040911B (en) 2011-11-18
ATE518520T1 (de) 2011-08-15
EP1201242A3 (en) 2003-12-03
EP1192946A1 (en) 2002-04-03
CY2617B2 (en) 2012-05-23
CN101164542A (zh) 2008-04-23
ATE531364T1 (de) 2011-11-15
NO963132L (no) 1996-09-26
HK1041829A1 (en) 2002-07-26
FI123580B (fi) 2013-07-31
ATE216243T1 (de) 2002-05-15
MY114665A (en) 2002-12-31
CA2182086C (en) 2000-04-11
EP2156840A2 (en) 2010-02-24
EP0740550A1 (en) 1996-11-06
SG47387A1 (en) 1998-04-17
JPH11286447A (ja) 1999-10-19
EP1174139A2 (en) 2002-01-23
JP2008031184A (ja) 2008-02-14
PL315575A1 (en) 1996-11-12
DE69526425D1 (de) 2002-05-23
ES2368827T3 (es) 2011-11-22
JPH09501700A (ja) 1997-02-18
FI122395B (fi) 2011-12-30
ATE525075T1 (de) 2011-10-15
TW329387B (en) 1998-04-11
CY2616B2 (en) 2012-05-23
PT1174138E (pt) 2011-10-03
ES2173947T3 (es) 2002-11-01
NO963132D0 (no) 1996-07-26
HU9602043D0 (en) 1996-09-30
EP1201242B1 (en) 2011-11-02
AU1727195A (en) 1995-08-15
EP1201242A2 (en) 2002-05-02
DE69526425T2 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
NO20025002D0 (no) Anvendelse av mometasonfuroat ved behandling av luftveis- og lungesykdommer
Janssens et al. Extra-fine particles improve lung delivery of inhaled steroids in infants: a study in an upper airway model
CY1109030T1 (el) Συνθεση για εισπνοη
TR200402367T4 (tr) Yeni tiotropyum içeren inhalasyon tozları
Lin et al. Aerosol delivery during spontaneous breathing with different types of nebulizers-in vitro/ex vivo models evaluation
Wildhaber et al. Salbutamol delivery from a hydrofluoroalkane pressurized metered-dose inhaler in pediatric ventilator circuits: an in vitro study
Blanco et al. AD Loppow et al.
WO1992011025A3 (en) Administering alpha interferon by oral inhalation to treat asthma and non-malignant proliferative pulmonary diseases
Blaiss Aerosols and delivery devices in asthma management
AnonMD University of Pittsburgh School of MedicineDepartment of OtolaryngologyPittsburghPA 15261USA
Nambu et al. EFFECTIVENESS OF EXTERNAL CHEST COMPRESSION ON INHALATION THERAPY IN ASYMPTOMATIC PERIODS FOR ASTHMATIC CHILDREN-PILOT STUDY

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY, US

MK1K Patent expired